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Abstract: Individuals with severe factor VIII deficiency experience recurrent hemorrhages 
and develop progressive joint damage. Large retrospective, nonrandomized studies of patient 
cohorts followed over decades show that factor prophylaxis initiated at an early age before 
the onset of recurrent bleeding reduces the incidence of hemophilic arthropathy. Two recent 
prospective, multicenter, randomized trials conducted in Europe (the ESPRIT study) and 
the USA (the Joint Outcome Study) confirm the efficacy of prophylaxis in the prevention 
of hemarthroses and arthropathy. Regular prophylaxis initiated in early childhood enhances 
the quality of life for patients with severe hemophilia and reduces the risk of inhibitor 
development. The substantial costs of such preventative therapy may be offset by the reduced 
expenditures that the care of degenerative joint disease in adult hemophilia patients would 
otherwise require.
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Introduction
Deficiency of factor VIII (FVIII) causes hemophilia A, the most common severe 
bleeding disorder in humans. FVIII plays a pivotal role in physiologic coagulation. 
It serves as a cofactor for factor IX, amplifying its catalytic activity by several orders 
of magnitude.
Hemophilia has been recognized since antiquity as a distinct clinical entity. Egyptian 
papyri and Hebrew Talmudic documents contain descriptions of this disorder. The first 
accurate account in the modern medical literature dates back to the early 19th century. 
The delineation of its genetic transmission and its characterization as hemophilia fol-
lowed soon thereafter.1 The discovery in 1937 that administration of normal plasma 
corrects the prolonged clotting time of hemophilic blood inaugurated the modern era 
of treatment and prophylaxis.2
Hemophilia, an x-chromosome linked disorder, occurs in 1 per 5,000 male births. 
Eighty-five percent of affected individuals have hemophilia A, which is caused by a 
wide range of FVIII gene mutations.3 Half of all patients have severe disease, defined 
as a factor level of 0.01 IU/mL (1%) or less. Bleeding episodes often occur with mini-
mal or unknown trauma. Ninety percent of patients suffer from recurrent hemorrhage 
into their joints or muscles, typically beginning in the toddler age. Once hemophilic 
arthropathy ensues, progressive joint damage leads to debilitating dysfunction and 
chronic pain.
Before the availability of clotting factor concentrates, the life expectancy of 
patients with severe hemophilia was markedly decreased.4–6 In contrast, patients Vascular Health and Risk Management 2010:6 60
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with moderate hemophilia, characterized by FVIII levels 
from 0.01 to 0.05 IU/mL (1% to 5%), by and large bleed 
only after trauma and experience near normal quality and 
length of life.
The advent of plasma-derived and recombinant 
technology-produced FVIII concentrates has revolutionized 
the care of individuals with severe hemophilia. This review 
focuses on the use of FVIII for the treatment and prophy-
laxis of hemarthroses, the clinical hallmark of this disease. 
Prophylaxis, a prerogative of developed countries because 
of the high cost of factor concentrates, has shifted the main 
objective of hemophilia treatment from avoidance of bleeding 
short-term to the prevention of secondary complications and 
preservation of long-term quality of life.
Principles of treatment  
and prophylaxis
Hemophilia therapy aims to treat and prevent acute bleeding 
episodes, to minimize related complications, and to maintain 
normal joint physiology.
On-demand factor infusion, also known as episodic 
therapy, is defined as therapy to abrogate an acute hemor-
rhage. Cessation of bleeding does not reverse the deleterious 
effects on synovial tissues by the blood already accumulated 
in the affected joint.
In patients without neutralizing inhibitor, each FVIII 
unit per kg body weight infused raises the plasma factor 
level by 2% points. FVIII levels sufficient for cessation 
of bleeding vary depending on the site and severity of the 
hemorrhage. Appropriate levels range from 30% to 50% 
for intra-articular, muscular, and mucosal bleeds to 100% 
for central nervous system hemorrhage. For the purposes of 
prophylaxis, FVIII trough levels of only 1% to 5% prove 
adequate.
Preventative factor infusion implies replacement therapy 
in advance of anticipated activity likely to result in bleeding 
in the otherwise unprotected individual. Prophylactic factor 
infusions aim to prevent bleeding episodes on an ongoing 
basis.
Secondary prophylaxis connotes therapy instituted after 
hemarthroses have already occurred, while primary prophy-
laxis is initiated before such bleeds ensue. According to the 
European Paediatric Network for Haemophilia Management 
(PEDNET), two definitions of primary prophylaxis are now 
in use. Primary prophylaxis A demands factor infusions after 
the first joint bleed but before the age of two years. Factor 
therapy initiated before the age of 2 years with no prior 
hemarthroses defines primary prophylaxis B.7 Prevention of 
joint degeneration rather than prevention of bleeding episodes 
constitutes the main goal of prophylaxis.
Factor VIII products
Following the 1964 landmark observation that slowly thawed 
frozen plasma contains a precipitate rich in FVIII, hence-
forth known as cryoprecipitate,8 plasma-derived (p/d) FVIII 
concentrates became available in the 1970s and 1980s.9 
These concentrates are now subjected to virus reduction and 
inactivation methods. The integration of ion-exchange and 
immuno-affinity chromatography into the manufacturing 
process further enhances the purity of FVIII and increases 
its specificity.
The rapid development and commercialization of recom-
binant clotting factors was facilitated by the catastrophic 
impact of viral contamination of p/d factor concentrates in 
the 1980’s. Characterization of the human factor VIII gene,10 
the molecular cloning of its cDNA,11 and the transfection 
of mammalian cells allowed the large-scale production of 
full-length recombinant FVIII preparations (rFVIII) and 
their use for human therapy.12,13 rFVIII products omit the 
requirement for human blood or plasma and offer freedom 
from viral transmission.
Despite the use of bovine or human albumin used as 
stabilizers in first and second generation rFVIII products, 
no viral transmission has been reported in decades of use. 
Second-generation recombinant factors, available since 
1999, contain nonprotein stabilizers but continue to use 
albumin in the initial cell culture. Third-generation prod-
ucts are manufactured without foreign animal or human 
protein from synthesis to final formulation.14 Recombinant 
factors derived from genetically engineered hamster ovary 
or kidney cells are purified with mouse monoclonal anti-
bodies and therefore pose the theoretical risks of animal 
pathogens.
Recombinant and p/d FVIII concentrates of different 
degrees of purity have shown similar behavior in vitro 
and equivalent clinical efficacy in bleeding control and 
prophylaxis. Head-to-head comparison studies of first- vs 
second-generation rFVIII products15 as well as second- vs 
third-generation products showed comparable results.16
Clinical trials with previously treated and untreated 
patients have documented safety and efficacy of rFVIII. The 
first large-scale trial of rFVIII for acute bleeding reported 
101 previously transfused patients, 64 of whom had severe 
hemophilia. After a median follow-up of almost five years 
since first exposure to rFVIII, treatment response was deemed 
excellent.17 In an updated report totaling 1,362 bleeding Vascular Health and Risk Management 2010:6 61
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episodes, 65% resolved past 1 infusion, and 92% past 1 
to 3 infusions.18 Equivalent hemostatic responses of more 
than 90% to 1 or 2 factor infusions were seen in subsequent 
trials with 7919 and 7115 previously untransfused as well as 
pretreated patients.20 A B-domain-deleted rFVIII product 
showed a pharmacokinetic profile equivalent to that of a full-
length monoclonal antibody-purified pd-FVIII, and similar 
hemostatic efficacy and safety.21
It has been emphasized that dosage requirements vary 
considerably among individual patients and that therapy 
requires adjustments based on clinical outcome (bleeding 
frequency and joint status) as some patients with factor lev-
els less than 1% do not bleed while others do despite trough 
levels of 3%.22
Prophylaxis in nonrandomized 
studies
Acute hemarthrosis is the clinical hallmark of hemophilia. 
Vessels of the synovial membrane bleed into the articular 
space spontaneously or with minimal trauma. Iron deposi-
tion precipitates an inflammatory reaction, the release of 
oxidative products, and vascular proliferation.23–25 Synovial 
hyperemia and hypertrophy lead to destruction of cartilage 
and bone. Degenerative arthritis, quantified by the Pettersson 
score,26 results in functional impairment and chronic pain. 
Joint disease reduces physical fitness and muscular strength, 
creates muscle atrophy, and in a vicious cycle exacerbates 
articular instability and repeated bleeding episodes. Chil-
dren with hemophilia may have reduced bone mineral 
density compared to age- and gender-matched controls.27 
Hemarthroses begin in the toddler age. Ankle, knee, and 
elbow joints are most commonly affected. The tendency to 
bleed correlates inversely with the endogenous FVIII level. 
Individual patterns of bleeding, however, vary substantially 
even in patients with FVIII levels of less than 1%, although 
most patients experience 15 or more spontaneous hemor-
rhages per year.
Long-term follow-up has shown progressive joint 
degeneration in more than half of patients within 6 years from 
the first bleeding episode, often necessitating restriction of 
activity. A linear relationship between the severity of arthropa-
thy and the cumulative number of intra-articular hemorrhages 
has been demonstrated.28–30
Recognition of the superior clinical outcome of patients 
with moderate hemophilia and factor levels even as low as 
1% or 2% suggested that a sustained therapeutic increase in 
factor levels in patients with severe disease and induction of 
a moderate clinical phenotype might improve hemostasis, 
favorably affect the frequency of hemarthroses, and prevent 
or at least delay the onset of degenerative arthritis.
Experience with cryoprecipitate infusions in Holland 
and Sweden suggested that hemarthroses can indeed be 
curtailed.31,32 Prophylactic p/d FVIII infusions effected a 
substantial reduction in the frequency of bleeding episodes. 
Lower dose infusions given daily were comparable to higher 
doses infused 3 times per week.33 Subsequent experience 
has proven that factor therapy initiated after the first several 
joint bleeds, now defined as secondary prophylaxis, can 
reduce further bleeding. Deterioration of joint anatomy 
and function, however, is irreversible.34 Despite stringent 
prophylactic therapy initiated as early as after 3 to 6 joint 
bleeds when baseline clinical and radiologic scores were 
still normal, follow-up at 3 years detected the development 
of arthropathy.35
Large retrospective cohorts followed over decades in 
several European countries have shown prophylaxis initi-
ated at an early age before the onset of recurrent bleeding to 
reduce hemophilic arthropathy. Swedish patients monitored 
longitudinally provided evidence that early prophylaxis 
aimed to produce FVIII trough levels above 0.01 U/mL 
translates into improved outcome. While such secondary 
prophylaxis did reduce the bleeding frequency, already 
established arthropathy did not only persist but worsened. 
In contrast, factor therapy initiated at the age of 1 to 2 years 
and given on a 2 to 3 times a week basis prevented arthropa-
thy in adulthood.36,37 The timing of initiation of prophylaxis 
independently predicted the development of arthropathy, 
whereas dose and infusion intervals did not. Treatment 
before the age of 3 years prevented arthropathy in most 
patients.38 Long-term follow-up of retrospective cohorts of 
Dutch29 and German35 patients corroborated the Swedish 
experience. No arthropathy developed in patients with one 
or no bleed prior to initiation of prophylaxis at the age of 
1 to 2 years. The later in life prophylaxis started, the more 
prevalent the arthropathy became. These data have led to the 
current definition of primary prophylaxis, ie, prophylaxis 
initiated before the age of 2 years and after no more than 
one joint bleed.7
Daily factor infusions have been calculated to be most 
effective, resulting in a substantial decrease in overall fac-
tor use.39 Such intensive therapy, however, imposes a heavy 
burden on patients and their families and cannot easily be 
sustained over years of treatment.
The original Swedish, high-dose, prophylactic factor regi-
men prescribed 25 to 40 IU/kg 3 times a week, targeting a pre-
infusion factor level exceeding 1%. In contrast, physicians Vascular Health and Risk Management 2010:6 62
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in Holland employed an intermediate-dose regimen with 
adjustments according to bleeding pattern irrespective of 
factor trough levels. Follow-up over 2 decades of boys born in 
these two countries from 1970 to 1990 revealed a reduction in 
hemarthroses at the expense of 2-fold higher factor consump-
tion in the Swedish compared to the Dutch cohorts.40
The Canadian Hemophilia Dose-escalation Prophylaxis 
trial also investigated an individualized, intermediate-dose 
therapeutic approach as an alternative to full-dose prophy-
laxis. In this 5-year study, 25 boys between the ages of 1 and 
2.5 years without inhibitors received prophylaxis. Initial 
therapy started at 50 IU/kg weekly (step 1) and escalated to 
30 IU/kg twice weekly (step 2) if a target joint developed 
(defined as three bleeds into a single joint) or if bleeding 
frequency was deemed intolerable (four joint and/or signifi-
cant soft tissue bleeds) over a 3-month period. Persistence 
of bleeding prompted escalation to full prophylaxis (step 3). 
After a median follow-up of 46.4 months, 36% of patients 
escalated to step 2, and 16% progressed to step 3. Joint out-
come data as defined by the Pettersson score were observed 
to be good over the study period.41 An updated report on this 
tailored prophylaxis was recently published.42 After a median 
follow-up of 4.1 years, the median time to escalate to twice-
weekly therapy was 3.4 years. Nine of the 25 boys developed 
target joints. On average, patients experienced 1.2 joints 
bleeds per person-year and consumed 3656 IU/kg/year. At 
the end of the study period, clinical and radiographic joint 
examination scores were normal. The investigators concluded 
that most boys will have little bleeding and maintain good 
joint function on tailored prophylaxis with reduced FVIII 
consumption.
Based on these early experiences and apparent ben-
efits of prophylaxis, the World Health Organization,43 the 
National Hemophilia Foundation,44 and the World Federa-
tion of Hemophilia45 all recommend preventative therapy 
in children.
Results of a multicenter nonconcurrent cohort study 
were published more recently.46 Forty-two children received 
primary prophylaxis following their first bleeding episode. 
Patients in this group were frequency-matched (year of 
birth, catchment area) with 67 patients receiving on-demand 
therapy with an early switch to secondary prophylaxis. In a 
multivariate analysis adjusted for hemophilia mutation type 
and presence or absence of thrombophilia, the Pettersson 
score was investigated at a median age of 12.5 years in joints 
with at least one documented bleeding episode. No statisti-
cally significant differences were identified between the two 
groups. The study investigators were unable to conclude a 
superior outcome of primary prophylaxis over on-demand 
therapy with an early switch to secondary prophylaxis. 
The interpretation of these results has been disputed as the 
investigators considered a bleeding history of only 6 months 
before the initiation of the study rather than a life-time, 
cumulative history of hemarthroses. Because of this mis-
leading definition of primary versus secondary prophylaxis, 
the protective effects of primary prophylaxis may have been 
underestimated.47
Practice patterns
Throughout the developed countries, practice patterns of 
FVIII therapy differ widely. Factors influencing therapy 
include the cost of factor concentrates, the perception of 
the advantages of such therapy, lifestyle and bleeding pat-
terns, the fear of complications from intravenous devices 
often required in young children with poor intravenous 
access, inhibitor development, and until recently, the lack 
of randomized clinical trials.
In the Netherlands and Sweden, primary prophylaxis is 
now almost universal. In Dutch patients under 16 years, pro-
phylaxis increased from 34% in 1972 to 86% in 2001, while 
hospital admissions decreased from 47% to 18%.48 A global 
survey of treatment practice patterns of more than 10,000 
pediatric and adult patients disclosed virtually all Swedish 
children receiving prophylaxis.49
The results of the 2006 Canadian national haemophilia 
prophylaxis survey revealed a similar trend.50 Among 
2161 patients, 69% received prophylaxis, defined as at least 
once weekly factor infusion for more than 45 weeks per 
year, including 84% of children and 55% of adults over 
18 years. In comparison to the Canadian 2002 survey, the 
use of prophylaxis in children less than 6 year increased from 
49% in 2002 to 73% 4 years later. In general, more people 
including adults were on prophylaxis, and prophylaxis started 
earlier as well.
In contrast, replacement therapy for hemophilia in Japan 
is far less common.51 Only 24% of boys under the age of 
2 among 1267 patients queried received primary prophylaxis, 
but half the patients aged 2 to 14 received secondary pro-
phylaxis. Surveys of treatment centers in the United States 
disclosed similarly low numbers.52 4129 patients in 52 centers 
showed 25% of children younger than 5 years and 13% of 
all patients on primary prophylaxis. A more recent investi-
gation revealed the prevalence of primary prophylaxis only 
slightly higher at 17%.53 Blanchette et al found discordant 
data in a query of North American hemophilia centers.54 
Seventy-seven percent of pediatric patients in Canada were Vascular Health and Risk Management 2010:6 63
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on primary prophylaxis versus 47% in the USA. Reasons for 
these divergent findings are unclear.
Prophylaxis in adulthood
Adherence to a prophylactic regimen and the rate of self 
infusion drop precipitously among young adults.53 Few pub-
lished studies address this issue. An investigation in Denmark 
and the Netherlands with 80 patients and a median follow-up 
of 19 years revealed that 35% discontinued prophylaxis at 
a median age of 21.5 years.55 These patients subsequently 
experienced only 3 joint bleeds per year. The median clinical 
and Pettersson scores of the cohorts on and off prophylaxis 
were identical at follow-up 4 years later.
A larger European survey of practice and outcome data 
identified a lack of consensus on discontinuation or modifi-
cation of prophylaxis in adolescent and adult patients.56 No 
consensus existed on the indication of reintroduction of pro-
phylaxis at a later stage of life. Approximately half of a cohort 
of 218 patients successfully reduced or stopped prophylaxis 
upon reaching adulthood. Twenty-six of 92 (28%) patients 
who stopped prophylaxis required reintroduction of therapy. 
Twelve of 59 (20%) of those who reduced the intensity of 
prophylaxis had to reintroduce a more rigorous regimen. The 
survey revealed the preferred age of modification to be 16 to 
20 years. No consensus existed on the particular prophylactic 
regimen recommended.
Data from these studies indicate clinical features sug-
gestive of a milder bleeding phenotype in those patients 
who were able to permanently switch to on-demand therapy, 
including later age at start of prophylaxis, a lower-dose factor 
regimen, and decreased incidence of breakthrough bleeds. 
These characteristics may be useful in identifying patients 
able to discontinue prophylaxis in early adulthood.
A majority of respondents would consider (re-) starting 
prophylaxis at age 50 years.
Tagliaferri et al assessed the effects of secondary prophy-
laxis started in adolescent and adult hemophiliacs. A 90% 
reduction in the mean annual number of joint bleeds in 
patients on prophylaxis accompanied an equal decrease in 
days lost from work or school.57 Compared to the patients 
on episodic factor therapy, individuals on prophylaxis had 
an increased consumption of factor concentrates with cor-
responding higher costs balanced by marked clinical benefits 
with improved quality of life.
It has been argued that the challenge in the care of young 
adults lies not in the discontinuation of prophylaxis but in 
optimizing the efficiency by individualizing prophylaxis 
doses and frequency according to life style and bleeding 
pattern.58 Lack of clinical trials and consensus led the Adult 
Prophylaxis Study Group to identify a compelling need for 
evidence-based guidelines.59
Randomized trials of hemophilia 
prophylaxis
Until two years ago, lack of data derived from well-designed 
prospective FVIII trials was cited as insufficient evidence for 
primary factor prophylaxis. Support for such prophylaxis 
in patients with severe hemophilia A came predominantly 
from the retrospective, comparative cohort studies outlined 
above. Four small randomized studies enrolled a total of only 
44 patients and were thus too limited to allow for definitive 
conclusions. One of these studies evaluated patients with 
hemophilia B and two were conducted over 30 years ago. The 
study designs precluded a meaningful meta-analysis due to 
divergent intervention and patient age.60–63
The results of two more recent, large, prospective, multi-
center, randomized clinical trials have been published in the 
last two years. In Europe, the ESPRIT study confirmed the 
feasibility and efficacy of prophylaxis in the prevention of 
hemarthroses and arthropathy.64 Forty children with severe 
hemophilia A (FVIII  1%) and a median age of 2 years were 
randomized to receive prophylaxis with 25 IU/kg 3 times a 
week with dose adjustments to maintain trough levels above 
1%, or on-demand therapy with a minimum of 25 IU/kg of 
FVIII concentrate. Compared to patients with on-demand 
therapy, children on prophylaxis had fewer bleeds in general 
(0.52 vs 1.08 bleeds/patient/month; P  0.05) and fewer 
hemarthroses (0.2 vs 0.52; P  0.02). Radiographic evalu-
ation disclosed hemophilic arthropathy in 29% of patients 
on prophylaxis compared to 74% of on-demand patients 
(P  0.05). Factor inhibitors developed in three prophylaxis 
and two on-demand patients.
Results of the Joint Outcome Study (JOS) conducted in 
the United States were published in 2007.65 This trial enrolled 
65 boys from 1996 to 2000. Eligibility criteria included age 
less than 30 months, a FVIII level of 2% or less, normal 
baseline radiographic studies, and no more than two prior 
hemorrhages in any index joint (knee, ankle, and elbow). None 
of the participants had a history of an inhibitor. Thirty-three 
patients on the on-demand treatment arm received 40 IU/kg 
at the onset of joint bleeding, 20 IU/kg each 24 and 72 hours 
after the initial infusion and then every other day until resolu-
tion of joint pain and impaired immobility. Thirty-two patients 
received prophylaxis with 25 IU/kg every other day. The 
primary outcome measurement was the number of patients in 
each cohort with radiographic (MRI and plain-film) evidence Vascular Health and Risk Management 2010:6 64
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of bone or cartilage damage in the index joints at the age of 
6 years. Ninety-three percent of the boys in the prophylaxis 
group as opposed to 55% of individuals in the episodic treat-
ment group had normal index-joints.
High-titer factor inhibitors developed in two patients 
receiving prophylactic infusions. Three patients on episodic 
therapy sustained life threatening hemorrhages.
Interestingly, the number of clinically evident joint bleed-
ing episodes correlated only weakly with the outcome as 
measured by MRI studies. The investigators concluded that 
the absence of overt hemarthroses and joint abnormalities on 
physical examination may lead to the erroneous assumption 
that on-demand factor infusions in younger boys are effective. 
They postulated that repeat microhemorrhages may cause 
damage without obvious evidence of heamarthroses.
While the results of alternate day prophylaxis were clearly 
superior to enhanced episodic factor therapy, the investiga-
tors were cognizant of the high cost of this preventative 
approach. Factor consumption in the prophylaxis group was 
almost 2.5-fold higher than in the on-demand group (6000 vs 
2500 units per year).
Inhibitor development
After the arrival of recombinant technology-derived factor 
products with minimal risk of transmission of infectious 
pathogens, the development of inhibitors is now the most seri-
ous treatment-related complication of hemophilia therapy.
Inhibitors render normal therapy ineffective and hem-
orrhage more difficult to control. They lead to increased 
morbidity and mortality and higher cost.
Patient-related determinants of inhibitor development 
include ethnicity, family history and, most importantly, the 
individuals’ FVIII gene mutation.3 Several severe genetic 
defects (large deletions, nonsense mutations, FVIII intron 
22 inversions) result in absence of clotting factor. In these 
patients, exogenous factor therapy represents exposure to a 
foreign antigen and may elicit a high-titer, FVIII neutralizing 
immune response.
Approximately 30% of patients with severe hemophilia 
A develop a factor inhibitor17,19 although in individual series, 
the rate was as low as 2.7%66 and as high as 52%.67 Most 
inhibitors occur in early childhood with the highest risk 
within the first twenty exposure days.17,18,68–70
Earlier cohort studies suggested an inverse relationship 
between the age at first exposure and the probability of 
inhibitor development.71,72 Later studies with multivariate 
analyses adjusted for other variables including family history 
of inhibitor development as well as FVIII gene mutation did 
not confirm these results.73,74 To the contrary, children starting 
prophylaxis before the age of three years experienced a 70% 
reduction in the risk of inhibitor development.73
The CANAL study confirmed the protective effects 
of prophylaxis.74 Three hundred and sixty-six consecutive 
patients born between 1990 and 2000 were enrolled in this 
multicenter retrospective cohort study designed to assess 
the relationship between type of therapy and inhibitor 
development. A clinically relevant inhibitor was defined as 
the occurrence of at least 2 positive inhibitor titers com-
bined with a decreased factor recovery. Eighty-seven (24%) 
patients developed inhibitors, 69 of whom suffered from 
a high titer antibody. The incidence of inhibitors initially 
appeared to be associated with the age at first treatment. 
Forty-one percent of those treated within the first month of 
life developed an inhibitor compared to only 18% in those 
treated after 18 months. After adjustment for treatment 
intensity, this association largely disappeared. Surgical 
procedures and intensive treatment at first FVIII exposure 
substantially increased the inhibitor risk. In contrast, regular 
prophylaxis was associated with a 60% lower risk than on-
demand treatment.
The fear that patients would experience an increased prob-
ability of developing an inhibitor after switching from a p/d 
factor to a recombinant product has not been substantiated.75 
The Canadian surveillance study followed 479 previously 
treated patients for 1 year past conversion to a recombinant 
factor, and 339 for 2 years.76 No increase of new inhibitors 
was seen, suggesting that recombinant products do not pres-
ent epitopes different from those on p/d products.
The recognition of the protective effects of early low-dose 
prophylaxis has led many centers to pursue an incremental 
FVIII dosing approach in which patients initially receive once 
a week prophylaxis unless bleeding develops.77 Over a several 
months period, the infusion frequency is then increased to 
twice or three times a week therapy.
Consideration of cost in hemophilia 
prophylaxis
Although no consensus exists on the exact dosing schedule 
of prophylaxis, regular administration of recombinant FVIII 
in the pediatric age group is now accepted as the most effec-
tive treatment to prevent hemarthrosis, hospitalization, and 
arthropathy. Recent recommendations from the National 
Hemophilia Foundation extend the concept of prophylaxis 
as standard of care for severe hemophilia to patients of all 
ages. Epidemiologic data show improved care and long-term 
well-being in patients in general.Vascular Health and Risk Management 2010:6 65
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The high cost of rFVIII concentrate has been considered a 
major obstacle in the widespread acceptance of prophylaxis. 
In most countries of the developing world, such therapy is 
impractical, and even the reduced expense of p/d factor 
concentrates may be prohibitive. The presumed beneficial 
financial impact of markedly decreased hospitalization 
rates48 and a 60% to 70% lower risk of inhibitor development 
compared to on-demand therapy73,74 has not been quantified 
in these studies.
As the recent Joint Outcome study has shown,65 factor 
consumption of patients on routine prophylaxis exceeds that 
of episodic treatment 2.5-fold. The estimated annual cost 
of prophylaxis for a patient weighing 50 kg was thought to 
amount to US$300,000.
A cost-effectiveness study was recently published 
by investigators from Canada.78 Three distinct treatment 
regimens were investigated for their impact on incremental 
cost per joint-hemorrhage avoided, and on quality-adjusted-
life-year (QALY) gained. The treatments included standard 
prophylaxis, tailored (escalated) dose prophylaxis, and 
on-demand therapy. Costs considered in this analysis included 
factor concentrates, professional visits and tests, placement 
of central venous access and complications encountered, 
hospitalizations, home health care expenditures, and parents’ 
or caregivers’ work days lost. The costs of escalated-dose 
prophylaxis amounted to an additional US$3,000 per joint 
hemorrhage avoided compared to on-demand therapy, and 
US$9,000 for standard prophylaxis compared to on-demand 
therapy. The incremental cost per QALY for escalated 
dose vs on-demand therapy was US$542,000. Prophylaxis 
was thought to improve clinical outcome and quality of 
life compared to on-demand treatment but at a substantial 
increase in cost.
The increased life expectancy of patients now receiving 
safe factor concentrates without the risk of viral transmis-
sion will translate into health considerations not heretofore 
encountered. In essence, a disorder previously restricted by 
and large to the pediatric and young adult age group is now 
evolving into a disease of older adulthood with consequences 
reaching into geriatrics. Improperly treated hemophilia 
patients will pose great demands on national health care 
systems.
Expenditures related to an increased median annual fac-
tor consumption of patients on prophylaxis (3024 IU/kg vs 
780 IU/kg for on-demand treatment) may be offset by the 
reduced costs of fewer surgeries such as arthrodeses, implanta-
tion of prostheses, and synovectomies.79 These considerations 
do not take into account the additional positive economic 
effects of regular school attendance and uninterrupted 
work activities.
Children with severe hemophilia may have reduced 
bone mineral density (BMD) compared with age-matched 
controls,27 but prophylaxis starting in early childhood may 
preserve normal BMD and reduce the risk of degenerative 
bone disease, pathologic fractures, and the financial burden 
that such problems impose.80
The Economics Expert Working Group for the Inter-
national Prophylaxis Study Group has developed recom-
mendations for minimal core standards to be applied to the 
reporting of economic evaluations of hemophilia prophylaxis. 
These standards will facilitate the comparison of studies 
and allow rational policy decisions and treatment choices 
in the future.81
Conclusions
Nonrandomized as well as randomized studies have accu-
mulated a plethora of data on prophylactic FVIII infusions 
in patients with severe hemophilia A, documenting the 
beneficial results of decreased bleeding episodes and later 
degenerative joint disease. Nevertheless, a number of bar-
riers exist to implementation of such therapy as divergent 
practice patterns in the western world substantiate. Such 
barriers include inadequate intravenous access especially in 
young children, lack of understanding on the part of caregiv-
ers, fear of the development of an inhibitor, psychological 
factors, and not least the exorbitant cost of recombinant 
factor therapy.
Key questions as yet unanswered include the optimal age 
at onset of prophylaxis, the optimal dosage and schedule of 
infusions, and the proper clinical and laboratory follow up. 
Needed are prospective studies with different prophylactic 
regimens and objective outcome measures that take into 
consideration issues such as inhibitor development and cost 
of therapy.
As several recent prophylaxis studies with larger patient 
population have shown, bleeding episodes can be dramati-
cally curtailed82–85 only as long as patient compliance with the 
regimen is maintained.84,85 Lack of adherence to the intended 
regimen was the most important determinant of low FVIII 
levels and increased bleeding, although in children aged 1–6, 
the rate of hemorrhage was also influenced by the FVIII 
half-life and clearance.85
New factor preparations with extended half-life are in 
clinical studies. If proven effective, such factor concentrates 
will significantly decrease the frequency of factor infusions, 
thus likely increasing compliance. Gene therapy, now under Vascular Health and Risk Management 2010:6 66
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investigation, constitutes a possible alternative to prophylaxis, 
with curative potential.
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